PepGen has shared positive initial data from its ongoing FREEDOM-DM1 Phase I trial, which is evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In the 5mg/kg and 10mg/kg dose ...
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...
PARIS--(BUSINESS WIRE)--Genethon, a pioneering gene therapy research organization created by AFM-Telethon, today presented positive results from the Phase 1/2 dose escalation part of an international ...
Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals with small cell lung cancer (SCLC) and large cell ...
Tenaya Therapeutics, Inc., a biotechnology company focused on developing therapies for heart disease, will announce initial data from the MyPEAK-1 Phase 1b/2 clinical trial of its gene therapy TN-201 ...
Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...
Based on positive safety and efficacy data in the Phase 1/2 dose escalation phase of the all-in-one study, Genethon expects to launch pivotal trial in Europe in 2025 and in the US. The results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback